Evaluating the economic burden of psoriasis in the United States - 16/05/15
Abstract |
Background |
Psoriasis has significant economic impact on patients. However, its total economic burden has not been fully quantified.
Objectives |
To assess the annual economic burden of psoriasis in the United States.
Methods |
A systematic literature review was conducted to obtain estimates of the components of the economic burden of psoriasis. Prevalence estimates were used to estimate the 2013 psoriasis population. Incremental medical costs were calculated based on studies that compared psoriasis patients and controls. Productivity loss was estimated using measures of presenteeism, absenteeism, and unemployment. Reductions in health-related quality of life (HRQOL) were calculated from survey responses.
Results |
The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).
Limitations |
This study is constrained by the scope and populations of the existing literature.
Conclusions |
The economic burden of psoriasis in the US is significant, with a majority of it coming from indirect costs.
Le texte complet de cet article est disponible en PDF.Key words : disease burden, economic burden, presenteeism, prevalence, psoriasis, systematic review
Abbreviations used : CPI, ER, HRQOL, QALY, SF-12
Plan
| Supported by Novartis Pharmaceuticals Corporation. |
|
| Drs Vanderpuye-Orgle, Shrestha, and Sexton are employees of and Dr Seabury is a consultant at Precision Health Economics, which was compensated by Novartis to perform the study. Precision Health Economics provides consulting and other research services to pharmaceutical, device, governmental, and nongovernmental organizations. Dr Seabury also has received grant funding from the National Institute on Aging (P01 AG033559). Drs Zhao and Lu are Novartis employees. Dr Lebwohl has been an investigator and unpaid consultant for Abgenomics, Amgen, Anacor, Canfite Biopharma, Celgene, Coronado Biosciences, Dermira, Dermipsor, eli Lilly, Janssen Biotech, UCB Pharma, Leo-pharma, Merz, Valeant, Novartis, and Pfizer. |
|
| Appendices and Table A1 are available at www.jaad.org. |
Vol 72 - N° 6
P. 961 - juin 2015 Retour au numéro
Article précédent
- Answers to CME examination
- Psoriasis and risk of diabetes-associated microvascular and macrovascular complications
- April W. Armstrong, Annie Guérin, Murali Sundaram, Eric Qiong Wu, Elizabeth Sara Faust, Raluca Ionescu-Ittu, Parvez Mulani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?